Sitrin R G, Ansfield M J, Kaltreider H B
Exp Lung Res. 1985;9(1-2):85-97. doi: 10.3109/01902148509061530.
We demonstrated previously that surface-active material potently suppresses early proliferative responses of lymphocytes to a wide variety of immune stimuli in vitro. It is now evident that in vivo, effector B and T lymphocytes can be recruited into lung parenchyma subsequent to their generation in extrapulmonary lymphoid tissues. The purpose of the present study was to examine the effects of surface-active material on proliferation, differentiation, and expression of effector functions of cytotoxic T cells and antibody-forming B cells in vitro in order to gain insight into the potential immune regulatory role of surface-active material in vivo. Normal spleen lymphocytes were cultured in vitro for 5 days with either allogeneic lymphocytes to generate cytotoxic T cells or with sheep erythrocytes to generate antibody-forming B cells. Surface-active material was added at various intervals after the cultures were initiated, and the effects of such additions on the subsequent proliferation, differentiation, and expression of cytotoxic T cells and antibody-forming cells were determined. Addition of surface-active material on days 0 through 3 suppressed both lymphocyte proliferation and the subsequent differentiation of effector lymphocytes. By contrast, addition of surface-active material after day 3 exerted no measurable effect on proliferation or on the generation of effector lymphocytes. We conclude that in vitro the immunosuppressive activity of surface-active material is exerted primarily during early proliferative phases of immune responses and that once these have occurred, surface-active material does not inhibit the later stages of differentiation and expression of effector cell functions. We speculate that in vivo, surface-active material may suppress local proliferation of lymphocytes resident in the lung in response to inhaled antigens; however, it may not interfere with effector functions of partially or fully differentiated B and T lymphocytes that are recruited into lungs from systemic sources.
我们先前已证明，表面活性物质在体外能有效抑制淋巴细胞对多种免疫刺激的早期增殖反应。现在很明显，在体内，效应B淋巴细胞和T淋巴细胞在肺外淋巴组织中生成后可被募集到肺实质中。本研究的目的是在体外研究表面活性物质对细胞毒性T细胞和抗体形成B细胞的增殖、分化及效应功能表达的影响，以便深入了解表面活性物质在体内潜在的免疫调节作用。将正常脾淋巴细胞与同种异体淋巴细胞体外培养5天以生成细胞毒性T细胞，或与绵羊红细胞培养以生成抗体形成B细胞。培养开始后在不同时间间隔添加表面活性物质，并确定这种添加对随后细胞毒性T细胞和抗体形成细胞的增殖、分化及表达的影响。在第0天至第3天添加表面活性物质可抑制淋巴细胞增殖及随后效应淋巴细胞的分化。相比之下，在第3天之后添加表面活性物质对增殖或效应淋巴细胞的生成没有可测量的影响。我们得出结论，在体外，表面活性物质的免疫抑制活性主要在免疫反应的早期增殖阶段发挥作用，一旦这些阶段发生，表面活性物质不会抑制效应细胞功能的后期分化和表达。我们推测，在体内，表面活性物质可能抑制肺内驻留的淋巴细胞对吸入抗原的局部增殖；然而，它可能不会干扰从全身来源募集到肺中的部分或完全分化的B淋巴细胞和T淋巴细胞的效应功能。
